Noxopharm Limited ABN 50 608 966 123 Audited Financial Statements - 30 June 2026 Noxopharm Limited Directors' report 30 June 2026 1 The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated...
Audited Financial Statements
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- SOF-SKN to progress to extension study in CLE patients
- Investor Presentation September 2026
- Novel oligonucleotides data presented at Options Conference
- Appendix 4E - Preliminary Financial Report
- New preclinical data supports immuno-oncology approach
Later from Noxopharm
- FDA feedback supports SOF-SKN Phase II plans
- Annual Report to shareholders
- Appendix 4G and Corporate Governance Statement
- 2026 AGM Letter of Access, Notice of Meeting and Proxy
- Trading Halt
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm